Shamburg News · 8-K filed Oct 1, 2026, 8:10 AM EDT
Azitra Advances ATR-04 Phase 1/2 Trial to Cohort 2 After Safety Review Committee Clearance
AZTR · Azitra, Inc.
- Other event
- Materiality: medium
Azitra, Inc. announced on October 1, 2026 that its safety review committee recommended the Cohort 1 safety data supported proceeding to Cohort 2 of the Phase 1/2 trial of ATR04-484 for EGFR inhibitor-associated skin rash. The safety review was based on six patients, and Cohort 1 enrolled seven patients. Cohort 2 is expected to enroll approximately 24 patients receiving a 4g application once daily for 28 days. The announcement was furnished as Exhibit 99.1 under Item 8.01.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001493152-26-045260.
Written from the filing by Shamburg Markets. Figures are as reported by the company.